My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

52.86 -0.42 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US
The FDA has granted Fast Track Designation to BridgeBio Pharma Inc's (NASDAQ: BBIO) BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type... 
Via Benzinga
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors
From LianBio
Via Business Wire
Unusual Options Activity Insight: BridgeBio Pharma
BridgeBio Pharma (NASDAQ:BBIO) shares experienced unusual... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT 
Via Benzinga
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold
In a welcome move, biotech BridgeBio Pharma stock saw its Relative Strength Rating rise from 70 to 73 on Thursday. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy for Summer 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to. 
Via The Motley Fool
BridgeBio Stock Flashes Healthy 83 RS Rating
Look for stocks with a Relative Strength Rating of 80 or higher. BridgeBio stock just hit that mark, with a jump from 79 to 83 Wednesday. 
Via Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer
BridgeBio Pharma Inc (NASDAQ: BBIO), through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq (... 
Via Benzinga
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
From Helsinn Group
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.